GET DAILY SIGNALSWhy Is Karyopharm Therapeutics (KPTI) Stock Down -29.14% Today?
Key Takeaways
- KPTI shares are down roughly 29.14% in today's session, trading near $0.0389 versus a prior close of $0.0549.
- The decline extends a collapse triggered by the company's voluntary Chapter 11 bankruptcy filing and a planned merger with Ayrmid Ltd., announced November 2, 2026.
- Secondary pressure stems from a Nasdaq delisting notice and restructuring terms indicating common equity holders may recover nothing.
- The move reflects a distressed, speculative penny-stock situation rather than a change in the company's underlying clinical fundamentals.
- Traders are watching bankruptcy court proceedings, competing asset bids, and any delisting timeline for further price swings.
- For more detail on this ticker's valuation and outlook, explore our Price Targets, Earnings, and Forecast pages.
- Curious how automated strategies are navigating volatile names like this? Explore Tickeron's Trending AI Robots.
Opening Summary
Karyopharm Therapeutics Inc. (KPTI), a commercial-stage biopharmaceutical company best known for its XPO1 inhibitor XPOVIO (selinexor) used in multiple myeloma and myelofibrosis, saw its shares plunge again on Monday. The stock was trading near $0.0389 in the session, down about 29.14% from its previous close of $0.0549. The move is a continuation of a multi-day collapse that began after the company filed for Chapter 11 bankruptcy protection and unveiled a restructuring agreement to merge with Ayrmid Ltd.
Chapter 11 Filing and the Ayrmid Merger
The primary driver behind the sustained selloff in KPTI is the company's voluntary Chapter 11 filing on November 2, 2026, in the U.S. Bankruptcy Court for the Southern District of Texas. As part of that process, Karyopharm entered into a Restructuring Support Agreement with its lenders and noteholders providing for a merger between Ayrmid Ltd. and a reorganized Karyopharm. The company secured up to $55 million in debtor-in-possession financing, and the transaction is expected to close in the first quarter of 2027.
Markets reacted harshly because the restructuring framework effectively signals the end of value for existing shareholders. The company has said the prepackaged plan provides that holders of common stock and convertible preferred stock will not receive any payment or distribution, and that existing equity securities are expected to have no value. That reality has kept KPTI under relentless selling pressure since the announcement.
Nasdaq Delisting and Equity Wipeout Risk
Compounding the downward pressure, Karyopharm received a written delisting notice from Nasdaq following the bankruptcy filing. With delisting expected and the restructuring plan implying a complete loss for common equity, investors have continued to exit positions even at deeply depressed prices. Trading in the company's securities during the bankruptcy is highly speculative, and the market is pricing in minimal to zero recovery for ordinary shareholders.
Market Context and Trading Activity
The stock's decline has been accompanied by elevated volume well above its historical average, reflecting aggressive selling and speculative churn as traders reposition around the bankruptcy process. The move in KPTI is company-specific and has diverged sharply from the broader market and from most biotech peers, underscoring that the weakness is driven by the restructuring and delisting catalysts rather than general sector sentiment. Shares have broken through every recent technical support level and are trading near record lows.
What Comes Next for KPTI
The path ahead for KPTI hinges almost entirely on the bankruptcy process. The court will consider bidding procedures that would allow competing parties to submit proposals for the company's assets, with Ayrmid serving as the lead bidder. Investors will monitor court rulings, any competing bids, the delisting timeline, and whether the transaction closes as planned in early 2027. Key uncertainties include the pace of the proceedings, potential changes to the restructuring terms, and the final treatment of existing equity, which current plans indicate will receive no recovery.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Explore Trending AI Robots to see how automated strategies are adapting to today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for KPTI turns negative, indicating new downward trend
KPTI saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 86 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KPTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KPTI broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KPTI entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for KPTI just turned positive on October 19, 2026. Looking at past instances where KPTI's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
Following a +83.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where KPTI advanced for three days, in 222 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.004) is normal, around the industry mean (3.498). P/E Ratio (-0.004) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.226) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. KPTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KPTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation
Industry Biotechnology
Advertisement